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Abstract
Obesity, particularly in children and adolescents, has become a significant public health 
problem that has reached “epidemic” status worldwide. The etiology of obesity is com-
plex and involves lifestyle factors that are challenging to modify. The intestinal micro-
biota contribute to protection against pathogens, maturation of the immune system, and 
metabolic welfare of the host but, under some circumstances, can contribute to the patho-
genesis of certain diseases. Over the last decade, novel evidence from animal and human 
studies has identified associations between human intestinal bacteria and host metabo-
lism and obesity. Infancy is a critical period in the development of the gut microbiota: 
initial colonization is influenced not only by a number of early-life exposures, including 
birth mode, infant nutrition, or antibiotic use, but also by maternal factors during preg-
nancy, including maternal BMI, nutrition, gut microbial composition, and drug expo-
sure, among others. Thus, an adequate nutritional and microbial environment during the 
perinatal period and early life may provide windows of opportunity to reduce the risk of 
obesity and overweight in our children by using targeted strategies aimed to modulate 
the gut microbiota during early life.
Keywords: obesity, gut microbiota, early life, pregnancy, prebiotics, probiotics, 
antibiotics
1. Introduction
Obesity has become a major global health challenge because of the established health risks 
and substantial increases in prevalence. Urgent global action and leadership is needed to help 
countries to more effectively intervene [1]. This increase runs in parallel to an increase in the 
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obesity during pregnancy; moreover, due to the adverse effects that this condition has on both 
the mother’s and offspring’s health, infant obesity has become a highlight topic of study [2].
It is well known that the physiology during pregnancy differs between obese and normal-
weight women. Obesity is associated with increased insulin resistance, adverse effects in 
implantation and placentation processes, growth, development and metabolism alterations 
of the fetus, and even impact on the offspring gut microbiota [3].
Until now, studies focused on the origins of obesity were oriented towards dietary excesses 
(processed sugars, fat, and proteins) [4] or host genes [5]. But recent studies have shown 
changes in gut microbiota associated to different diseases, like obesity, metabolic syndrome, or 
type I [6] and type II diabetes [7]. The community of microorganisms living in a specific envi-
ronment is known as microbiota. These microorganisms include bacteria, Archaea, viruses, 
and some unicellular eukaryotes [8]. The collective genomes of the microorganism that con-
stitute the microbiota are known as microbiome [9]. The normal gut microbiota imparts spe-
cific function in host nutrient metabolism, xenobiotics, and drug metabolism, maintenance of 
structural integrity of the gut mucosal barrier, immunomodulation, and protection against 
pathogens [10]. In fact, some of these microorganisms residing in the gut encode proteins 
involved in functions important for the host’s health, such as enzymes required for the hydro-
lysis of otherwise indigestible dietary compounds, and the synthesis of vitamins [9]. Since the 
1990s, our knowledge of the complexity of this ecosystem has increased due to the advances 
in culture-independent techniques. These new techniques are fast, facilitate high through-
put, and identify organisms that are uncultured to date and present in the gut microbiota; 
recently, by using these techniques, it has been shown that alterations in the gut microbiota 
composition and function are associated with certain disease states, such as obesity [11]. With 
the increase in knowledge about gut microbiome functions, it is becoming increasingly more 
possible to develop novel diagnostic, prognostic, and most important therapeutic strategies 
based on gut microbiota manipulation.
Focused on obesity, it has been shown that certain bacteria metabolize different nutrients 
more efficiently than others, increasing the absorption of calories from the diet and the 
amount of energy usable for the host, which contributes to fat deposition [12]. Many stud-
ies have been performed in order to link this disease with changes in the composition of the 
intestinal microbiota [13]. Several studies have shown increased ratio in the proportion of 
Firmicutes/Bacteroidetes in genetically obese mice (ob/ob) and obese humans [14, 15]. However, 
other studies have failed to confirm these findings and showed variable patterns in the compo-
sition of the microbiota in obese humans [13]. Within the studies cited above, it is clear that the 
gut microbiota plays a role in obesity and metabolic disease, but it is difficult to draw defini-
tive conclusions about the importance of certain bacterial groups. It is therefore very impor-
tant to identify the active bacteria that cause dysbiosis in the gut microbiota in order to design 
therapeutic strategies for long-term protection against obesity. Quantitative and qualitative 
alterations in the composition of the gut microbiome could lead to pathological dysbiosis.
The microbiota colonization of the maternal intestine influences offspring’s metabolic and 
immune system development [16]. Besides, although the microbiota-gut-brain axis is not a new 
concept [17], in the last years there are growing interest in studying the influence of the microbiota 
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in children neurodevelopment by analyzing the microbiome impact on eating behavior, infant 
cognitive function, and brain structure and function [18]. However, the mechanisms by which 
maternal microbiota may contribute to health programming in the offspring are still unknown. 
The type of delivery (vaginal or caesarean section), diet [breast milk or formula], and antibiotics 
exposure have an influence on the offspring’s immune system that may promote the develop-
ment of chronic inflammation, leading to allergies, autoimmune diseases, like diabetes mellitus 
or rheumatoid arthritis, or noncommunicable diseases such obesity and their comorbidities in 
children [19–21].
In the present chapter, we aimed to update the knowledge about the factors involved in gut 
microbiota establishment during perinatal life, infancy and early childhood, and the relation-
ship to obesity development.
2. Maternal environment
There is evidence for the importance of the prenatal period in the health and development of 
offspring throughout childhood and adult life [22].
In the periconceptional period, and during pregnancy and lactation is necessary to acquire 
the total nutrient requirements, which are associated with mother’s lifestyles and health [23]. 
These requirements include specific amounts of iron, vitamins (D, C, and B), calcium, folic 
acid, essential fatty-acids, and others, which will increase along pregnancy [24]. Furthermore, 
it has been demonstrated that bad habits like smoking, use of illegal drugs, consumption of 
caffeine and alcohol, or overweight/underweight are related to conceiving problems [25].
During the first trimester of pregnancy, the mother is under anabolism, increasing maternal fat 
and nutrients storage to meet the fetus-placental and maternal requirements during gestation 
and lactation [26]. When a deficit or overabundance of nutrients arrives to the fetus, it has to 
adapt itself to the new metabolic status, changing its physiology and metabolism constantly [27].
It is noteworthy that due to fetal programing, obesity may become a self-perpetuating prob-
lem, because children of obese mothers may themselves be vulnerable to becoming obese and 
more likely to have offspring who share this vulnerability, but the mechanisms behind this 
association are not fully elucidated [28].
One hypothesis to explain the influence of the mothers’ weight on their children is the trans-
mission of obesogenic microbes from mother to her offspring; in this situation is also very 
important the etiology of such maternal obesity and others factors like socioeconomic status 
or environmental factors [29].
On the other hand, a meta-analysis including nine studies has shown an increased risk of 
stillbirth in obese pregnant women compared to normal-weight pregnant women [30].
It has been demonstrated that a high body mass index (BMI) and an excessive weight gain 
during pregnancy are associated with disturbances in the maternal gut microbiota, which will 
influence the development of gut microbiota in the infant [31].
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Infant gut microbiota will not be only influenced by mother’s BMI, but also by the mode 
of delivery [32]. A study indicated that excess maternal prepregnancy weight is associated 
with differences in neonatal acquisition of microbiota during vaginal delivery, enriched 
in genus Bacteroides and depleted in genus Enterococcus, Acinetobacter, Pseudomonas, and 
Hydrogenophilus [33].
Subsequent to delivery, it has been shown that the type of feeding is one of the major factors 
modulating infants gut microbiota and it will be discussed in Section 4.
The establishment of the microbial community allows the maturation of the immune system 
as it has been demonstrated in germ-free (GF) animal models, where commensal microorgan-
isms are required for the development of a fully functional immune system, which affects 
many physiological processes within the host [34].
In conclusion, the mother environment influences the offspring phenotype of her offspring, 
independently of his genotype. So, not only genetics will influence offspring gut microbiota 
development, but also mother’s lifestyle before, during, and after pregnancy.
3. Gut colonization and microbiota establishment in infancy
The first few weeks of life are very important for the gut colonization in the infant. This pro-
cess will be influenced by maternal factors (weight gain during pregnancy, BMI, nutrition, 
microbiome composition), intrauterine state (microbiota of amniotic fluid), type of delivery 
(caesarean or vaginal), type of feeding later (breast milk or infant formula), and antibiotic 
exposure, among others (Figure 1).
Traditionally, the placenta had been considered a sterile organ but current studies have 
reported the existence of a placental microbiome [35–37]. Although the origin of the bacteria 
colonizing the placenta is unclear, it has been shown that the microbial community is rep-
resented by members of nonpathogenic bacteria from the phylum Proteobacteria, Firmicutes, 
Bacteriodetes, Fusobacteria, and Tenericutes [38].
Recently, placenta microbiota has been associated with preeclampsia development during 
pregnancy and with preterm birth, which highlights the importance of the close relation-
ship between the microbiota and pregnancy [39]. A placental dysbiosis during pregnancy as 
a consequence of excess weight gain could have a major influence on the colonization and 
establishment of gut microbiota community on the infant [40].
Because these findings are very recent, the effects of the bacterial profile modification by pro-
biotic supplementation during pregnancy and the effects on placental microbiome modula-
tion are still unknown and further studies are needed.
After birth, it is known that meconium is not sterile and harbors a particular microbial com-
munity, characterized by a higher abundance of Firmicutes compared to Proteobacteria in early 
fecal samples [41].
A study showed that the mode of delivery (caesarean or vaginal) did not affect the diversity of 
the microbiota from meconium, in contrast, these samples presented a lower species  diversity 
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and a higher variation among samples in comparison with adult feces [42]. These results 
indicate that the microbial contact during perinatal life may imprint the offspring microbiota 
and immune system in preparation for the much larger inoculum transferred during vaginal 
delivery and breast-feeding.
As mentioned in the previous section, the mode of delivery is going to favor the establishment 
of a specific microbiota. Previous studies have demonstrated that gut microbiota of infant 
born through vaginal delivery is similar to maternal gut and vaginal microbiota; conversely, 
the infants born by caesarean section have a gut community more similar to bacteria from 
maternal skin or the hospital environment [43].
Figure 1. Maternal and environmental elements affecting the onset and modulation of the gut microbiota in the newborn 
infant. A plethora of factors during pregnancy can negatively influence the neonate’s gut microbiota composition and 
function. Furthermore, environmental factors, such as mode of delivery and feeding modality can significantly drive the 
neonate’s gut microbiota.
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Regarding the mode of delivery, epidemiological studies suggest that caesarean delivery is 
associated with increased risk of overweight and obesity later in life [44]. A study has found 
that caesarean section delivery was associated with adiposity at 6 weeks of age, being this 
association stronger in children born from obese mothers and having higher risk of obesity 
and overweight at 11 years old [45]. Although the mode of delivery may affect the coloniza-
tion of the intestinal microbiota in the baby and will increase the risk for later obesity devel-
opment, it has been found that perinatal exposition of the infant born by caesarean section 
respect to the vaginal discharge, can partially restore its gut microbiota and resembles to 
babies born by vaginal delivery avoiding the problems that this entails [46].
The microbiota of the babies by the end of the first year of life presents a different microbial 
profile in comparison to adults. The initial gut composition of the infant is simple, dynamic, 
and very unstable and undergoes marked fluctuations influenced by external factors [47]. At 
the beginning, the gut environment is aerobic, but through colonization, the oxygen level is 
reduced generating a suitable environment for the growth of anaerobes [48]. The intestinal 
microbiota of neonates is characterized by low diversity and a relative dominance of fac-
ultative anaerobes of the phyla Proteobacteria and Actinobacteria [49]. After birth, the phyla 
Firmicutes and Bacteroidetes increase their diversity and dominance, reaching over 3 years old 
a total resemblance to the adult in terms of composition and diversity [50]. These results indi-
cate that dietary intake during the first 1500 days of life is a critical factor in the establishment 
of gut microbiota community and its role in the development of obesity is a matter of research 
and discussion.
4. Type of infant feeding
Another important factor modulating microbial colonization in infants is the type of feed-
ing. The diet during early life will influence on the establishment and composition of the gut 
microbiota during childhood and even adult life [51]. Breast milk meets the infant’s needs by 
providing nutrients appropriate to the infant’s developmental stage, as well as growth fac-
tors, antimicrobial peptides, and proteins to support their developing immune system. Even 
though breast milk provides all the necessary nutrients for a suitable development of the 
baby, many babies cannot take it for several reasons and they are fed with infant formulas. 
Infant formulas provide a greater weight gain and increase the risk of obesity, hypertension, 
and diabetes [52]. Therefore, it is necessary to continue studying the composition and the 
positive effects of breast milk versus milk infant formula in order to better understand the 
beneficial role of breast milk on offspring’s health to improve the outcomes in the formula-fed 
infants.
Breast-feeding brings clear short-term benefits for child health by reducing mortality and 
morbidity from infectious diseases. There is evidence on the effects on child health and 
growth of exclusive breast-feeding for 6 months. Kramer et al. showed that infants who 
were exclusively breast-fed for 6 months experienced lower morbidity from gastrointestinal 
and allergic diseases, while showing nondeficits in growth rates to non–breast-fed children 
[53]. Based on such evidence, WHO and UNICEF recommend that every infant should be 
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exclusively breast-fed for the first 6 months of their life; continued breast-feeding for up to 
2 years or longer is also recommended [54]. Also, there is evidence of long-term benefits of 
breast-feeding such as increased school achievement and performance in intelligence tests, 
reduced mean blood pressure, lower total cholesterol, and a lower prevalence of overweight 
and obesity leading to lower incidence of inflammatory bowel diseases, type 2 diabetes, and 
obesity later in life [54, 55].
Human milk is a dynamic fluid that contains many hundreds to thousands of distinct bioactive 
molecules that confers beneficial properties for infants. Human milk changes in composition 
from colostrum to late lactation, and varies within feeds, diurnally, and between mothers [56].
The composition of this complex mixture differs also during the lactation period, from colos-
trum through transitional to mature milk. Colostrum is produced during the first days of 
postpartum, it contains high amounts of secretory IgA, lactoferrin, leukocytes, and epidermal 
growth factor. Transitional milk typically occurs from 5 days to 2 weeks postpartum, it shares 
some of the characteristics of colostrum but there is an increase in milk production to support 
the nutritional and developmental needs of the rapidly growing infant. By 4–6 weeks post-
partum, human milk is considered fully mature and it remains stable in composition over the 
course of lactation [57–59]. Thus, infant formula should adapt to different physiological and 
nutritional needs of the growing baby.
Regarding the gut microbiota acquisition, the first colonizers of the infant gut are faculta-
tive anaerobes including Staphylococcus, Streptococcus, Escherichia coli, and Enterobacteria that 
will be later replaced by strict anaerobes that dominate the gastrointestinal tract, primarily 
Clostridium, Bifidobacterium spp., and Bacteroides [60]. This change in dominant taxa represen-
tation can be attributed to the introduction of breast milk or formula-feeding, signifying the 
first diet-related colonization event in the infant gut microbiome [61, 62]. Breast milk has 
been shown to be an excellent and continuous source of potentially beneficial and commensal 
bacteria, including Staphylococci, Streptococci, lactic acid bacteria, and Bifidobacteria, with bacte-
rial cell numbers reaching 103–105 ml–1 of breast milk. Although the commensals’ origin is 
unknown, it is inevitable that bacterial from mother’s skin are transferred to the baby during 
breast-feeding, but there is also other hypothesis wherein bacteria from the maternal gut may 
reach the mammary glands via maternal dendritic cells and macrophages [63]. More than 700 
species of bacteria have now been identified in human colostrum and breast milk, including 
multiple species of lactic acid bacteria as well as species typically colonizing the oral cavity 
of infants [64].
The presence of Bifidobacteria in breast milk is important for the colonization of the infant 
gut, since it mediates the activation of IgA-producing plasma cells in the human neonatal 
intestine. It is well established that a gut microbiota dominated by Bifidobacteria typifies that 
of the healthy breast-fed infant [65]. There are conflicting results regarding differences in the 
relative abundance of these bacteria between breast- and formula-fed infants. Many stud-
ies have reported that formula-fed infants display dominance of Bifidobacterium spp. similar 
to what has been observed in breast-fed infants [61, 66]. However, another study reported 
approximately double the count of Bifidobacterium in breast-fed infants compared to those 
formula-fed [67].
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Comparisons between breast-fed and formula-fed infants show that breast-fed infants tend 
to contain a more uniform population of gut microbes dominated by Bifidobacteria and 
Lactobacillus [67], whereas formula-fed infants exhibit higher proportions of Bacteroides, 
Clostridium, Streptococcus, Enterobacteria, and Veillonella spp. [66–69].
Although infant formulas have evolved greatly during last years, a formula providing exactly 
the same benefits than human milk has not yet been developed. Among others, human milk 
contains substantial quantities of complex nondigestible oligosaccharides (known as human 
milk oligosaccharides, HMOs). HMOs are considered a type of prebiotics as they promote the 
growth and proliferation of beneficial commensals and, consequently, prevent pathogen colo-
nization of the infant gut and exert positive health effects [70]. Thus, the chemical composition 
of breast milk does influence the gut microbiome through supplying oligosaccharides that are 
selectively utilized by specific bacteria in the gut [60].
Another way to modify the gut microbiome is by the administration of probiotics. Probiotics 
are defined as “live microorganisms which when administered in adequate amounts, confer a 
health benefit to the host” [71]. Lactobacillus and Bifidobacterium species isolated from human 
milk are the most commonly used probiotic strains. They exert beneficial properties in the 
gut by suppressing the proliferation of pathogenic microbes, has been extensively studied 
[72]. For this reason, another area of research regarding formula enrichment is in HMOs and 
probiotics and their effects on the infant gut microbiota.
Certain gut-associated bacterial populations such as Bifidobacterium spp. possess gene clusters 
dedicated to the metabolism of HMOs [73, 74]. Degradation of these compounds produces lactate 
and short-chain fatty acids (SCFA), which in turn generates an acidic environment that prevents 
pathogen invasion [75]. Besides Bifidobacteria, HMOs may be consumed by other species such as 
Bacteroides spp. (e.g., Bacteroides fragilis and Bacteroides vulgatus) that consumes a broad range of 
HMO glycans [76]. Thus, HMOs play an important role in the gut colonization of the infants.
Among the most common prebiotics are fructo-oligosaccharides (FOS),  galacto- oligosaccharides 
(GOS), inulin, and lactulose. The prebiotic mixture of 90% GOS plus 10% FOS has been 
assessed to be safe when added to infant formula [77]. Several randomized controlled trials 
have been made to evaluate the efficacy and safety of prebiotic supplementation in infant 
formulas [78, 79]. After compiling data of these trials into a meta-analysis, weight gain 
[weighted mean difference 1.07 g/day] was significantly higher among formula-fed infants 
supplemented with prebiotics compared to the placebo group [80]. In addition, a large num-
ber of clinical trials in term of infants have shown controversial results related to the increase 
in Bifidobacteria in feces due to supplementation of infant formula with GOS and FOS. A sys-
tematic review published by Rao et al. [78] reported that some of the randomized controlled 
trials (RCTs) showed a trend of increasing Bifidobacteria counts in formula supplemented fed 
infants, and another systematic review published by Mugambi et al. [81] failed to show the 
increase in Bifidobacteria or Lactobacillus or the decrease of pathogens in infants fed with pre-
biotic supplemented formula.
Nonetheless, there are promising results from studies which have assessed the effect of prebi-
otic supplemented formulas on the gut microbiota of infants. Prebiotics are able to change gut 
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metabolic activity, bring stool consistency, and defecation frequency closer to that of breast-
fed infants. Other outcomes included better weight gain and softer stools, and a significant 
reduction in stool pH for infants who received prebiotic supplementation [78, 81]. Moreover, 
prebiotics have been used to prevent or treat obesity. Compared to probiotics, human studies 
with prebiotics have shown more promising results in obesity management, with reductions 
in body weight and fat mass in adults [82–84] in contrast with results from meta-analysis 
mentioned above, where the supplementation with prebiotics was significantly associated to 
a higher weight gain [80].
In the last years there is a growing interest in the simultaneous administration of prebiotics and 
probiotics, what is termed “symbiotic.” There are a few recent studies which have assessed 
the effect of symbiotic supplementation on the infant health. The ESPGHAN Committee on 
Nutrition showed an increase in stool frequency for three types of symbiotic (B. longum BL999 
plus GOS/FOS, B. longum BL999 plus L. rhamnosus LPR plus GOS/FOS, and L. paracasei subsp. 
paracasei plus B. animalis subsp. lactis plus GOS) [79]. Also, Ringel-Kulka et al. showed that a 
yogurt with the probiotic bacteria Bifidobacterium animalis subspecies lactis (BB-12) and the 
prebiotic inulin significantly reduced days of fever, improved social and school functioning, 
and increased frequency of bowel movements in healthy children attending child care centers 
[85]. Regarding to obesity interventions with symbiotic, Safavi et al. [86] found that treatment 
of overweight children with a symbiotic mixture of the prebiotic, FOS, in combination with 
seven probiotic strains was associated with a decreased BMI z-score compared to placebo.
Studies suggest that pre-, probiotic, and symbiotic supplementation may be beneficial in the 
prevention and management of disease where the gut microbiota has a key role (e.g., necrotiz-
ing enterocolitis, gastroenteritis, or obesity). Although these studies show promising benefi-
cial effects, the long-term risks or health benefits of pre- and probiotic supplementation are not 
clear as results from single studies need to be replicated in well-defined RCTs. Nonetheless, 
there is active research on functional food that contains pre-, probiotics, and symbiotics sup-
plementation because they can influence not only the microbiota favoring the growth of ben-
eficial microorganisms, but also the mucosal immune system associated to the gut [87].
5. Childhood exposure to antibiotics
Exposure to antibiotics during infancy and childhood use to begin very early. Two different 
studies showed that >30% of women with a delivery had done systemic antibiotic treatments 
during pregnancy [88, 89]. Although the effects of antibiotic exposure during pregnancy on 
acquisition of infants’ microbiota have not been established, maternal antibiotic exposure is 
relevant since infants’ microbiota is taken at least in part from their mothers. In addition, pre-
natal antibiotic exposure has been shown to have effects on the birth weight of neonates and 
is associated with increased risk of obesity and related metabolic sequelae later in life [90, 91].
After birth, a number of neonates, particularly premature infants, receive antibiotics to pre-
vent or treat bacterial infections. Fjalstad et al. showed that 2.3% of all live-born term infants 
received intravenous antibiotics in the population, they analyzed from 2009 to 2011 [92]. 
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Higher prescription rates were shown in preterm or term infants with relevant clinical prob-
lems. In a study involving neonates admitted to the neonatal intensive care unit in U.S. from 
2005 to 2010, more than 88% of extremely low birth weight infants were administrated anti-
biotics [93].
Over the last decade, several national and international health institutions have made an 
enormous effort to decrease antibiotic use in the pediatric population by educating parents 
about the futility of treating viral infections with antibiotics and about concerns of antibiotic 
resistance [94, 95]. But, despite a recent reduction, widespread antibiotic use in infants and 
children remains a relevant health problem in the entire industrialized world, mainly because 
most prescriptions were frequently inappropriate [96].
However, even in countries in which the prescribing pattern usually adheres to national 
guidelines with respect to the choice of antibiotics, antibiotics are still largely prescribed to 
children, particularly to very young children [97–100].
In addition to antibiotic exposure for infection prevention and therapy, children could poten-
tially be substantially exposed to antibiotics through the food supply chain or, more rarely, 
drinking water [101].
5.1. Evidence from animals
In last 50 years, farmers have been using low doses of antibiotics to promote growth and 
feed efficiency of pigs, cows, sheep, and poultry [102]. Different antibiotics have been demon-
strated to have these effects independently of its class, chemical structure, and mode of action 
and spectrum of activity. Moreover, the effects on growth are greater when animals receive 
antibiotics early in life than if the exposure occurs later in life [103–105].
Also, studies in mice using multiple types of antibiotics have further confirmed this associa-
tion, as well as identifying early life as the key period for microbe-mediated programing of 
host metabolism [106, 107].
Experiments with germ-free animal models have provided direct evidence of the key role 
of the microbiota in the association between low doses of antibiotics exposure and growth 
promotion. In 1963, Coates et al. showed that in germ-free chicken antibiotics alone have no 
growth promoting effects [108]. Recently, Cox et al. showed that germ-free mice who received 
the microbiota from mice treated with low dose penicillin gained more weight and fat mass 
than mice colonized with microbiota from control animals [107].
Then, there are two main findings from these experiments. First, early life is a critical time for 
metabolic development of the host, and second, the microbiome has a key role in this process 
and its disturbance duty to antibiotic exposure at this time affects the course of growth and 
development [109].
5.2. Epidemiologic evidence
There is epidemiologic evidence that exposure to antibiotics in early life is associated with 
increased risk of excess adiposity. Recently, epidemiological studies have shown that 
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this phenomenon can also occur in humans starting in the fetal stage of life. In that sense, 
Mueller et al. observed in a U.S. cohort that the administration of antibiotics to women in 
the last two trimesters of pregnancy increased 84% the risk of obesity in children at 7 years 
old compared to children born to mothers without antibiotics administration at the same 
period [110]. Also, Mor et al. observed similar results in a study performed in Denmark 
where they showed that prenatal exposure to systemic antibacterials was associated with an 
increased risk of overweight and obesity at school age, and this association varies by birth 
weight [111].
After birth, the exposure to antibiotics has been associated to obesity due to the analysis of 
different human cohorts in various countries. In a Danish mother-child pairs cohort, Ajslev 
et al. showed antibiotic exposure in children during the first 6 months was associated with 
an increased risk of being overweight at 7 years of age; the effect was stronger in boys than 
in girls. In a U.K. cohort, Trasande et al. showed that antibiotic use in the first 6 months of 
life was associated with increased BMI at 10, 20, and 38 months of age [19]. Both studies 
also determined that maternal BMI was a contributing factor for the development of obesity 
following exposure to antibiotics in early life, with increased effects seen in children with 
mothers of normal weight compared with children from mothers who were overweight. Also, 
Azad et al. in a study of Canadian infants showed that antibiotics administered in the first 
year of life increased the likelihood of a child being overweight at 9 years and 12 years of age 
being almost seen in boys [112], which was consistent with the previous results from Ajslev 
et al. In a U.S. cohort, Bailey at al. observed that repeated exposure to broad-spectrum anti-
biotics at ages 0–23 months was associated with early childhood obesity. Importantly, this 
observation was associated with the use of broad-spectrum antibiotics, but not with the use 
of narrow-spectrum antibiotics.
Finally, in a multicenter, multicountry, cross-sectional study (The International Study of Asthma 
and Allergies in Childhood Phase III) Murphy et al. observed a significant interaction between 
sex and early-life antibiotic exposure. Exposure to antibiotics during the first 12 months of life 
was associated with a small increase in BMI in boys aged 5–8 years but not in girls in this large 
international cross-sectional survey.
Colonization of neonate’s gut microbiota relies on vertical transmission from the mother at 
the time of delivery; thus, during pregnancy or early-life exposure to antibiotics could have 
effects on weight later in life by disturbing the proper establishment of the gut microbiota.
5.3. Antibiotic exposure and dysbiosis in children
Prospective studies have showed that changes in gut microbiota in early life may precede the 
development of overweight and obesity [113, 114].
In particular, some bacterial taxa has been associated with the risk of obesity development, 
regarding to this, a high abundance of intestinal Bifidobacteria in early life appears to be asso-
ciated with lower risk of overweight [114, 115], whereas high amounts of Bacteroides fragilis 
increase the risk of obesity development [113]. Thus, likely factors that exert an impact on gut 
microbiota composition and functionality in early life may also modulate the risk of obesity 
development.
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Therefore, antibiotic exposure during childhood can reduce the phylogenetic diversity and 
microbial load of the gut microbiota [116].
Regarding preterm infants it has been shown that treatment with amoxicillin and gentamicin 
during the first week of life reduced the bacterial diversity and raised the relative abundance 
of Enterobacter in the second and third weeks of life compared to preterm infants not exposed 
to antibiotics [117].
Moreover, administration of penicillin, ampicillin, cephalexin, gentamicin, amikacin, eryth-
romycin, vancomycin, clindamycin, and teichomycin to preterm infants has been associ-
ated with a decrease in the relative abundance of Bifidobacteriaceae, bacilli, and Lactobacillales 
spp., commonly linked with a healthy status and an increase in the presence of potentially 
pathogenic Enterobacteriaceae [117–119]. Besides short-term-effects, the dysbiosis produced 
by antibiotics administration in infants may produce long-term effects like the persistence 
of the risk of obesity development. It has been observed that 3 months after of antibiotics 
persists the microbiota disruption [120]. However, antibiotic administration to neonates has 
been linked to several critical clinical conditions in which modification of the microbiota 
composition is thought to play a relevant role, in diseases such as necrotizing enterocolitis 
and sepsis [121, 122].
Antibiotic treatments in early life can lead to long-term alterations in microbiota composition 
that result in changes to host metabolic functions, particularly during development, increas-
ing the risk of obesity [109].
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